Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) (BAT-RAD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04704505
Recruitment Status : Not yet recruiting
First Posted : January 11, 2021
Last Update Posted : April 9, 2021
Sponsor:
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Tracking Information
First Submitted Date  ICMJE January 7, 2021
First Posted Date  ICMJE January 11, 2021
Last Update Posted Date April 9, 2021
Estimated Study Start Date  ICMJE May 2021
Estimated Primary Completion Date May 2025   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 8, 2021)
Radiographic progression-free survival (rPFS) of BAT-RAD [ Time Frame: 24 months ]
To determine the radiographic progression-free survival (rPFS) of BAT-RAD in patients with mCRPC treated with at least one novel androgen receptor (AR) targeted treatment.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: January 8, 2021)
  • PSA decline ≥ 50 percent rate (PSA50) of BAT-RAD [ Time Frame: 24 months ]
    To determine the PSA decline ≥ 50% rate (PSA50) of BAT-RAD in patients with mCRPC in 24 months.
  • Change in alkaline phosphatase of BAT-RAD [ Time Frame: Baseline and then on day one of each cycle (each cycle is 28 days), up to 9 cycles ]
    To determine if the dynamics (change) of alkaline phosphatase of BAT-RAD in patients with mCRPC.
  • PSA progression-free survival (PSA-PFS) of BAT-RAD [ Time Frame: 24 months ]
    To determine the PSA progression-free survival (PSA-PFS) of BAT-RAD in patients with mCRPC in 24 months.
  • Time to disease progression of BAT-RAD [ Time Frame: 24 months ]
    To determine the time to disease progression of BAT-RAD in patients with mCRPC measured in months.
  • Overall survival of BAT-RAD [ Time Frame: 24 months ]
    To determine the overall survival of BAT-RAD in patients with mCRPC in 24 months.
  • Symptomatic skeletal event-free survival [ Time Frame: 24 months ]
    To determine the symptomatic skeletal event-free survival in patients with mCRPC in 24 months.
  • Change in Quality of life as assessed by anxiety/depression EuroQol 5 dimensions 3 levels (EQ-5D-3L) [ Time Frame: Baseline, cycle 4 day 1, cycle 7 day 1 and at the end of treatment, up to 28 days post cycle 9 (each cycle is 28 days) ]
    The EQ-5D-3L is made up of 5 questions each with 3 levels. The lowest level being none and the highest level being extreme. Overall score range of 3-15 with higher scores signifying worse quality of life.
  • Change in Quality of life as assessed by the Functional Assessment of Cancer Therapy- Prostate (FACT-P) [ Time Frame: Baseline, cycle 4 day 1, cycle 7 day 1 and at the end of treatment, up to 28 days post cycle 9 (each cycle is 28 days) ]
    The (FACT-P) is made up of 39 question the scoring is between 0 and 156 with 0 being the best and 156 as the worst.
  • Change in Quality of life as assessed by the Brief Pain Inventory-Short Form (BPI-SF) [ Time Frame: Baseline, cycle 4 day 1, cycle 7 day 1 and at the end of treatment, up to 28 days post cycle 9 (each cycle is 28 days) ]
    The Brief Pain Inventory-Short Form (BPI-SF) is 1 question 0 being the best and 10 being the worst.
  • Safety of BAT-RAD in patients with mCRPC as assessed by number of participants removed for adverse events [ Time Frame: Up to 10 months ]
    To determine the safety of BAT-RAD in patients with mCRPC in patients with mCRPC compared with standard of care treatment for this patient population. This will be measured through Physical assessment, adverse events and labs and will be measured by how many patients are removed for adverse events.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures
 (submitted: January 8, 2021)
Percentage of patients with somatic (tumor) or germline (inherited) mutations [ Time Frame: 24 months ]
To estimate the percentage of patients with somatic (tumor) or germline (inherited) mutations in homologous repair (HR) and/or mismatch repair (MMR) genes in patients with mCRPC.
Original Other Pre-specified Outcome Measures Same as current
 
Descriptive Information
Brief Title  ICMJE Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
Official Title  ICMJE Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) (BAT-RAD Study)
Brief Summary This is a single-arm, multicenter open label, international, phase II study of Bipolar Androgen Therapy (BAT) plus Radium-223 (RAD) in men with metastatic castration-resistant prostate cancer (mCRPC). Men with mCRPC with progressive disease (radiographically and/or biochemically) who have been treated with gonadotropin-releasing hormone (GnRH)-analogue (LHRH agonists/antagonists) continuously or bilateral orchidectomy will be enrolled in this study. Previous antiandrogen therapies are permitted, but no more than one (such as abiraterone, enzalutamide, apalutamide, darolutamide). All patients will receive treatment with Radium-223 at a dose of 55 Kilobecquerel (kBq) per kilogram of body weight IV every 28 days, for 6 cycles, plus Testosterone Cypionate 400mg Intramuscular (IM) every 28 days, until progression or unacceptable toxicity.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Prostate Adenocarcinoma
  • Metastatic Prostate Adenocarcinoma
  • Castration-resistant
Intervention  ICMJE
  • Radiation: radium-223
    Radium-223 is an alpha-particle-emitting bone-targeted therapy. All patients will receive Treatment with Radium-223 at a dose of 55 kBq per kilogram of body weight IV every 28 days, for 6 cycles,
  • Drug: Bipolar Androgen Therapy (BAT)
    All Patients will receiveTestosterone Cypionate 400mg IM every 28 days, until progression or unacceptable toxicity.
Study Arms  ICMJE Experimental: Bipolar Androgen Therapy in addition to RADium-223 (RAD)
Participants will receive Bipolar Androgen Therapy (BAT) plus Radium-223 (RAD).
Interventions:
  • Radiation: radium-223
  • Drug: Bipolar Androgen Therapy (BAT)
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Not yet recruiting
Estimated Enrollment  ICMJE
 (submitted: January 8, 2021)
47
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE May 2026
Estimated Primary Completion Date May 2025   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Histologically documented adenocarcinoma of the prostate confirmed by pathology report from prostate biopsy or a radical prostatectomy specimen. If prostatic tumor is of mixed histology, > 50% of the tumor must be adenocarcinoma.
  • Bone metastases as manifested by one or more lesions on a Technetium 99m bone scan performed within 2 months of screening
  • Castrate-resistant prostate cancer, in the setting of castrate levels of testosterone (≤ 50 ng/dL), defined as current or historical evidence of disease progression concomitant with surgical castration or androgen deprivation therapy (ADT), as demonstrated by two consecutive rises in PSA OR new lesions on bone scan:
  • PSA progression will be defined as 2 rising PSA values compared to a reference value, measured at least 7 days apart and the second value is ≥ 2 ng/mL. Appearance of one or more new areas of abnormal uptake on bone scan when compared to imaging studies acquired during castration therapy or against the precastration studies if there was no response. Increased uptake of pre-existing lesions on bone scan does not constitute progression. It must be documented within 8 weeks of screening Documented bone lesions by the appearance of ≥ 2 new lesions by bone scintigraphy or dimensionally measurable soft tissue metastatic lesion assessed by CT or MRI.
  • Serum PSA ≥ 2.0 ng/mL
  • Patients must be on bone health agents, either zoledronic acid or denosumab, for at least 4 weeks before enrollment. These treatments must then be continued during the study.
  • Screening Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
  • Asymptomatic or minimally symptomatic disease (no opioids)
  • Prior treatment with no more than one novel AR targeted drug (abiraterone, enzalutamide, darolutamide or apalutamide) is permitted, but not required. Prior first-generation AR targeted therapies such as bicalutamide or nilutamide are permitted as previous therapy and does not count as novel AR targeted therapy.
  • Prior chemotherapy for hormone-sensitive prostate cancer (given ≥ 12 months prior to study entry) is allowed, but not necessary.
  • Adequate bone marrow, renal and liver function (Absolute Neutrophil count > 1,000, Platelets >100,000, Hemoglobin ≥ 9g/dL aspartate aminotransferase/ alanine amino transferase (AST)/(ALT) within normal limits (WNL); Total Bilirubin WNL.
  • No evidence (within 5 years) of prior malignancies (except successfully treated basal cell or squamous cell carcinoma of the skin).
  • All patients must have tissue for genomic analysis. A biopsy of a metastatic site may be done during the screening; however, archive tissue will be allowed. Prostate tissue from prostate biopsy will be allowed.

Exclusion Criteria:

  • The presence of known visceral metastasis, including lung, liver and brain metastases.
  • Spinal cord compression, imminent long bone fracture, or any other condition that, in the opinion of the investigator, is likely to require radiation therapy and/or steroids for pain control during the active phase.
  • Previous treatment with chemotherapy for mCRPC, or chemotherapy for any reason within 12 months prior to registration. (Chemotherapy in the adjuvant setting or for hormone-sensitive prostate cancer is permitted, as long as it was completed more than 6 months before registration).
  • History of radiation therapy, either via external beam or brachytherapy within 28 days prior to registration.
  • Systemic therapy with strontium-89, samarium-153, rhenium-186 or rhenium-188 for the treatment of bony metastases within previous 24 weeks
  • Use of opioid analgesics for cancer-related pain such as oxycodone, morphine or methadone. Weak opioid analgesics such as codeine or tramadol are permitted.
  • Use of experimental drug within 4 weeks of treatment.
  • Patients with an intact prostate AND urinary obstructive symptoms are excluded (which includes patients with urinary symptoms from benign prostatic hyperplasia (BPH).
  • Patients receiving anticoagulation therapy with warfarin are not eligible for study. Patients on other anticoagulants such as rivaroxaban, dabigatran, apixaban are permitted.
  • Symptomatic nodal disease, i.e. scrotal, penile or leg edema.
  • Poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease, or active, uncontrolled infection or a disease that may compromise safety. Examples include, but are not limited to, diabetes, heart failure, chronic obstructive pulmonary disease (COPD), ulcerative colitis, or Crohn's disease, Paget's disease, ventricular arrhythmia, recent (within 12 months) myocardial infarction, thromboembolic events or any psychiatric disorder that prohibits obtaining informed consent. Any medical intervention, any other condition, or any other circumstance which, in the opinion of the investigator, could compromise adherence with study requirements or otherwise compromise the study's objectives.
  • Evidence of disease in sites or extent that, in the opinion of the investigator, would put the patient at risk from therapy with testosterone (e.g. femoral metastases with concern over fracture risk, severe and extensive spinal metastases with concern over spinal cord compression, etc). Patients with low volume visceral metastasis are permitted at the discretion of the investigator, however bone disease must be predominant.
Sex/Gender  ICMJE
Sexes Eligible for Study: Male
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: Rana Sullivan, RN 410-614-6337 rtomali1@jh.edu
Contact: Amber Michalik, AA 410-502-0756 amichal2@jhmi.edu
Listed Location Countries  ICMJE Brazil,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04704505
Other Study ID Numbers  ICMJE IRB00273010
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study Sponsor  ICMJE Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Pedro Isaacsson Velho, M,D Moinhos de Vento Hospital
Principal Investigator: Samuel Denmeade, M,D Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins Hospital
PRS Account Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Verification Date January 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP